

# Charikleia Kranidioti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6831535/publications.pdf>

Version: 2024-02-01

14  
papers

194  
citations

1478505

6  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

371  
citing authors

#	ARTICLE	IF	CITATIONS
1	A typical autoimmune hepatitis (AIH) case following Covid-19 mRNA vaccination. More than a coincidence?. <i>Liver International</i> , 2022, 42, 254-255.	3.9	20
2	Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab588.	0.9	7
3	Endotoxin Translocation and Gut Barrier Dysfunction Are Related to Variceal Bleeding in Patients With Liver Cirrhosis. <i>Frontiers in Medicine</i> , 2022, 9, 836306.	2.6	7
4	<sc>HERACLIS</sc>: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 702-712.	3.7	6
5	Long-term clinical outcome of HBsAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. <i>Liver International</i> , 2021, 41, 48-57.	3.9	6
6	Direct-acting antiviral treatment for chronic hepatitis C in people who use drugs in a real-world setting. <i>Annals of Gastroenterology</i> , 2020, 33, 195-201.	0.6	9
7	Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogues. <i>Annals of Gastroenterology</i> , 2020, 34, 73-79.	0.6	4
8	Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBsAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 697-709.	2.0	17
9	Clinical and epidemiological characteristics of hepatitis C virusinfected people who inject drugs: a Greek descriptive analysis. <i>Annals of Gastroenterology</i> , 2018, 31, 598-603.	0.6	2
10	Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , 2017, 37, 1642-1650.	3.9	13
11	KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C. <i>Science Immunology</i> , 2017, 2, .	11.9	78
12	" Bacterial infections in patients with liver cirrhosis: clinical characteristics and the role of C-reactive protein". <i>Annals of Gastroenterology</i> , 2017, 31, 77-83.	0.6	6
13	Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors. <i>Annals of Gastroenterology</i> , 2015, 28, 173-181.	0.6	17
14	Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience. <i>Annals of Gastroenterology</i> , 2015, 28, 481-6.	0.6	2